TNFR2

TNFR2 분자 정보

영어 이름Tumor necrosis factor receptor superfamily member 1B시판 약물 수1
임상 약물 수8표적 별명TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
최고 연구 개발 단계Approved
영어 이름Tumor necrosis factor receptor superfamily member 1B
표적 별명TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
시판 약물 수1
임상 약물 수8
최고 연구 개발 단계Approved

TNFR2분자 배경

TNFR2 (tumor necrosis factor receptor superfamily member 1B) is a receptor with high affinity for TNFSF2/TNF-alpha. It has a much lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. TNFR2 mediates most of the metabolic effects of TNF-alpha.

TNFR2분자 별명

TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
LBL-019LBL-019Phase 2 ClinicalNanjing Leadsbiolabs Co LtdNeoplasms
상세
BI-1910BI-1910Phase 2 ClinicalBioinvent International AbCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours
상세
BITR-2101BITR-2101; BIR-2101; BITT2101; BITT-2101Phase 1 ClinicalBoston Immune Technologies & TherapeuticsInfections; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms
상세
TRB-061TRB-061Phase 1 ClinicalTrex Bio IncColitis; Dermatitis; Dermatitis, Atopic
상세
NBL-020Phase 1 ClinicalShanghai Xinshi Biological Medicine Co LtdNeoplasms; Solid tumours
상세
BC-011BC-011Phase 1 ClinicalDragonboat BiopharmaceuticalSolid tumours
상세
SIM1811-03SIM1811-03; SIM0235; SIM-235Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co LtdLymphoma, T-Cell, Cutaneous; Neoplasms; Solid tumours
상세
EmunkitugHFB-2003; HFB-200301Phase 1 ClinicalHiFiBiO TherapeuticsCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Germinoma; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Testicular Neoplasms; Uterine Cervical Neoplasms
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)ApprovedHisun Biopharmaceutical Co LtdMainland ChinaSpondylitis, Ankylosing; Psoriasis; Arthritis, RheumatoidHisun Biopharmaceutical Co Ltd2015-04-09Arthritis, Rheumatoid; Psoriasis; Spondylitis, Ankylosing
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호